Results 101 to 110 of about 4,898 (191)

Evaluation of antibiofilm activity of cefiderocol alone and in combination with imipenem against Pseudomonas aeruginosa [PDF]

Objectives: The main aim of this study was to evaluate the antibiofilm activity of cefiderocol alone and in combination with imipenem vs. sessile cells of Pseudomonas aeruginosa, assessing a potential synergistic bactericidal effect.
Cesta N., Rindi L., Ferretti C., Tavanti A., Bernardo M., Tascini C., Di Luca M., Poma N. V.   +7 more
core   +1 more source

In vitro activity of cefiderocol against Gram-negative aerobic bacilli in planktonic and biofilm form–alone and in combination with bacteriophages

Scientific Reports
Multi-drug resistant Gram-negative pathogens are increasingly difficult-to-treat perpetrators of infections. New, innovative, and more multifaceted therapies for the treatment of multi-drug resistant strains are thus urgent to hinder further drug ...
Rima Fanaei Pirlar, Nexhmije Halili, Tina Travnik, Andrej Trampuz, Svetlana Karbysheva   +4 more
doaj   +1 more source

Small colony variants and cefiderocol resistance in clinical <i>Escherichia coli</i>: an <i>in vitro</i> mechanistic study. [PDF]

Front Microbiol
Syed MA, Pu D, Song R, Zhao J, Cao B.
europepmc   +1 more source

Nutrient-driven small-colony variants as an adaptive outcome in Carbapenem-resistant <i>Acinetobacter baumannii</i>. [PDF]

Curr Res Microb Sci
Moheb S, Sanchez SD, Luu I, Varnado A, Traglia GM, Lopez K, Escalante J, Rodriguez C, Tuttobene MR, Tolmasky ME, Bonomo RA, Actis LA, Rao GG, Pasteran F, Ramirez MS.   +14 more
europepmc   +1 more source

Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes. [PDF]

J Antimicrob Chemother
Cantón R, García-Castillo M, Hernández-García M, Sastre-Femenía MÀ, López-Causapé C, Ruiz-Garbajosa P, García Labrador L, Longshaw C, Oliver A.   +8 more
europepmc   +1 more source

Innovative Antibiotics: The Experience of Cefiderocol in Carbapenem-Resistant Gram-Negative Infections. [PDF]

Infect Drug Resist
Melchio M, Briano F, Sepulcri C, Vena A, Bassetti M.   +4 more
europepmc   +1 more source

Unraveling Cefiderocol Resistance in NDM- and OXA-48-like Co-Producing <i>Klebsiella pneumoniae</i> Isolates Through Integrated Genomic and Phenotypic Analysis. [PDF]

Antibiotics (Basel)
Ambretti S, Cetatean R, Secci B, Landi J, Cantiani A, Foschi C.   +5 more
europepmc   +1 more source

Eravacycline-Cefiderocol Combination Therapy for Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infective Endocarditis: A Case Report and Brief Review of the Literature. [PDF]

Infect Drug Resist
Lou L, Li X, Zhang P, Wu H, Chen H, Ma J, Zhang K.   +6 more
europepmc   +1 more source

Cefiderocol in Children with Hematologic Malignancies-The Multicenter Retrospective Experience of the Infection Working Group of the Italian Pediatric Hematology and Oncology Association (AIEOP). [PDF]

J Clin Med
Muggeo P, Galaverna F, Chiusaroli L, Perruccio K, Coccia P, Baccelli F, Boccieri E, Rosignoli C, De Leonardis F, Santoro N, Cesaro S.   +10 more
europepmc   +1 more source

Cefiderocol Targeted Treatment for Multidrug-Resistant Gram-Negative Infections: An Observational Cohort Study. [PDF]

Antibiotics (Basel)
García-Carnero L, Abelenda-Alonso G, Santos-Puig M, Padullés A, Ribera C, Lamiel A, Costa-Primo R, Aledo MG, Granada R, Gumucio VD, Santafosta E, Gilabert M, Blanco-Arévalo A, Puig-Asensio M, Shaw E, Carratalà J, Gudiol C.   +16 more
europepmc   +1 more source